Processa Pharmaceuticals Files 8-K: Material Agreement & Shareholder Vote
Ticker: PCSA · Form: 8-K · Filed: Jun 30, 2025 · CIK: 1533743
| Field | Detail |
|---|---|
| Company | Processa Pharmaceuticals, Inc. (PCSA) |
| Form Type | 8-K |
| Filed Date | Jun 30, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, shareholder-vote, filing
Related Tickers: PCSA
TL;DR
Processa Pharma (PCSA) filed an 8-K for a material agreement and shareholder vote on June 24th.
AI Summary
On June 24, 2025, Processa Pharmaceuticals, Inc. entered into a material definitive agreement. The company also submitted matters to a vote of its security holders and filed financial statements and exhibits. The filing was made on June 30, 2025.
Why It Matters
This 8-K filing indicates significant corporate actions, including a new material agreement and shareholder voting, which could impact the company's strategic direction and financial future.
Risk Assessment
Risk Level: medium — Material definitive agreements and shareholder votes can introduce significant changes and uncertainties for a company.
Key Players & Entities
- Processa Pharmaceuticals, Inc. (company) — Registrant
- June 24, 2025 (date) — Date of earliest event reported
- June 30, 2025 (date) — Filing date
- Delaware (jurisdiction) — State of incorporation
- 45-1539785 (identifier) — I.R.S. Employer Identification Number
- 001-39531 (identifier) — Commission file number
FAQ
What type of material definitive agreement did Processa Pharmaceuticals, Inc. enter into?
The filing states that Processa Pharmaceuticals, Inc. entered into a 'Material Definitive Agreement' but does not specify the nature of the agreement in the provided text.
What matters were submitted to a vote of security holders?
The filing indicates that matters were submitted to a vote of security holders, but the specific details of these matters are not provided in the excerpt.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on June 24, 2025.
What is the principal executive office address for Processa Pharmaceuticals, Inc.?
The principal executive offices are located at 601 21st Street, Suite 300, Vero Beach, FL 32960.
What is the filing date of this 8-K report?
This 8-K report was filed as of June 30, 2025.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 30, 2025 regarding Processa Pharmaceuticals, Inc. (PCSA).